| P2093 | author name string | Krupa Shah | |
| | Lauren J Gleason | |
| | Amneris E Luque | |
| P2860 | cites work | Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review | Q22242702 |
| | Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 |
| | American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults | Q24620909 |
| | Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study | Q46568560 |
| | Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers | Q46638490 |
| | Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers | Q46801339 |
| | Elevated blood pressure in subjects with lipodystrophy | Q46815125 |
| | Racial differences in end-stage renal disease rates in HIV infection versus diabetes | Q46839522 |
| | Cushing's syndrome with adrenal suppression induced by inhaled budesonide due to a ritonavir drug interaction in a woman with HIV infection | Q48424453 |
| | Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection | Q48676425 |
| | Prescribing for the elderly. Part I: Sensitivity of the elderly to adverse drug reactions | Q39627241 |
| | Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas | Q42055798 |
| | Sexual dysfunction in 156 ambulatory HIV-infected men receiving highly active antiretroviral therapy combinations with and without protease inhibitors | Q42677677 |
| | Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. | Q42694082 |
| | Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir | Q42941908 |
| | Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. | Q43144867 |
| | Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy | Q43512126 |
| | Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection | Q43651001 |
| | Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir | Q43760231 |
| | Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey | Q43853947 |
| | Prescription drug use, diagnoses, and healthcare utilization among the elderly | Q44332153 |
| | Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone | Q44346297 |
| | Severe prolonged sedation associated with coadministration of protease inhibitors and intravenous midazolam during bronchoscopy: a commentary | Q44456641 |
| | Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial | Q44548030 |
| | Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors | Q44778139 |
| | Risk factors for adverse drug events among older adults in the ambulatory setting. | Q44991030 |
| | Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients | Q45229364 |
| | Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City | Q45730280 |
| | Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers. | Q45923416 |
| | Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy. | Q45971154 |
| | Influence of hospitalization on drug therapy in the elderly | Q46066582 |
| | Polypharmacy and prescribing quality in older people | Q46248077 |
| | Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. | Q50761727 |
| | Potentially inappropriate medication use and healthcare expenditures in the US community-dwelling elderly. | Q50803121 |
| | Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. | Q51088676 |
| | Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. | Q51371500 |
| | Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease. | Q51549675 |
| | Galactose elimination capacity and liver volume in aging man. | Q51624454 |
| | Chronic renal failure among HIV-1-infected patients. | Q51914547 |
| | A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. | Q53625973 |
| | The effect of age upon liver volume and apparent liver blood flow in healthy man. | Q53846028 |
| | Cardiovascular disease in HIV-positive patients. | Q53861364 |
| | Hospital admissions due to adverse drug reactions. A report from the Boston Collaborative Drug Surveillance Program. | Q54488031 |
| | Ageing with HIV: medication use and risk for potential drug-drug interactions | Q56525467 |
| | Effect of Alendronate on HIV-Associated Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled, 96-Week Trial (ANRS 120) | Q56762679 |
| | Clinically significant drug interactions in the HIV-infected elderly | Q56897780 |
| | Antiretroviral therapy adherence and drug–drug interactions in the aging HIV population | Q57990925 |
| | Atypical Antipsychotics and Parkinsonism | Q58070663 |
| | Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the | Q58375437 |
| | Potentially Inappropriate Medication Use Among Elderly Home Care Patients in Europe | Q60685626 |
| | Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses | Q67251864 |
| | A method for assessing drug therapy appropriateness | Q67976706 |
| | The development of human benign prostatic hyperplasia with age | Q72743475 |
| | Discrepancies in the use of medications: their extent and predictors in an outpatient practice | Q74029919 |
| | Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients | Q74312725 |
| | Supplemental insurance and use of effective cardiovascular drugs among elderly medicare beneficiaries with coronary heart disease | Q74608010 |
| | Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey | Q77327861 |
| | Drug-drug interactions in the elderly | Q78422796 |
| | Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects | Q79448424 |
| | Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers | Q80967856 |
| | Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America | Q81739951 |
| | Nine key questions to address polypharmacy in the elderly | Q81788573 |
| | HIV in older adults | Q82860307 |
| | Cushing's syndrome due to antiretroviral-budesonide interaction | Q84072814 |
| | Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection | Q84656730 |
| | Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin | Q95423232 |
| | Fatal adverse drug events: the paradox of drug treatment | Q28189532 |
| | Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers | Q28247644 |
| | Emergency hospitalizations for adverse drug events in older Americans | Q28253788 |
| | Adherence to Medication | Q28314923 |
| | Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies | Q29616299 |
| | Updating the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults | Q30050268 |
| | The impact of medication regimen factors on adherence to chronic treatment: a review of literature | Q30436145 |
| | Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir | Q32067953 |
| | Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. | Q33148910 |
| | Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension | Q33162013 |
| | Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study | Q33521080 |
| | Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status | Q33827543 |
| | Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview | Q33844000 |
| | Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse | Q33917628 |
| | Meta-analysis of the relationship between HIV infection and risk for depressive disorders | Q33944822 |
| | High prevalence of benign prostatic hypertrophy in the community | Q34001274 |
| | The natural history of benign prostatic hyperplasia: what have we learned in the last decade? | Q34080438 |
| | Suboptimal prescribing in older inpatients and outpatients | Q34156396 |
| | Managing medications in clinically complex elders: "There's got to be a happy medium". | Q34311242 |
| | Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance | Q34441791 |
| | Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine | Q34598599 |
| | Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe | Q34612352 |
| | Explicit criteria for determining potentially inappropriate medication use by the elderly. An update | Q34742065 |
| | Psychiatric disorders in older primary care patients | Q34749822 |
| | Potential interaction involving warfarin and ritonavir | Q34756237 |
| | Drug interactions between antiretroviral drugs and comedicated agents | Q35072074 |
| | Incidence and preventability of adverse drug events among older persons in the ambulatory setting | Q35080020 |
| | Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions | Q35088160 |
| | Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients | Q35168318 |
| | Physician-patient communication about prescription medication nonadherence: a 50-state study of America's seniors | Q35683265 |
| | QT prolongation with antimicrobial agents: understanding the significance | Q35771493 |
| | HIV infection and advanced age emerging epidemiological, clinical, and management issues | Q35784866 |
| | Use of selective serotonin-reuptake inhibitors in the treatment of depression in adults with HIV. | Q35962033 |
| | Urine volume and change in estimated GFR in a community-based cohort study | Q35985887 |
| | Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir | Q36094057 |
| | Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies | Q36154208 |
| | Optimizing treatment of hypothyroidism | Q36198436 |
| | Optimising drug treatment for elderly people: the prescribing cascade | Q36246842 |
| | Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects | Q36295441 |
| | Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. | Q36486076 |
| | Antimicrobial-associated QT interval prolongation: pointes of interest | Q36655034 |
| | Polypharmacy: misleading, but manageable | Q36897474 |
| | Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? | Q36942966 |
| | Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy | Q36951993 |
| | Polypharmacy in elderly patients | Q37052260 |
| | Association of tenofovir exposure with kidney disease risk in HIV infection | Q37077982 |
| | Variability in pharmacy interpretations of physician prescriptions | Q37187808 |
| | Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. | Q37194705 |
| | Aging issues in drug disposition and efficacy | Q37208594 |
| | Pharmacologic consideration for the use of antiretroviral agents in the elderly | Q37277510 |
| | The use of phosphodiesterase 5 inhibitors with concomitant medications. | Q37321940 |
| | Warfarin-antiretroviral interactions | Q37386503 |
| | Pharmacist-based medication review reduces potential drug-related problems in the elderly: the SMOG controlled trial | Q37394082 |
| | Epidemiology of HIV and response to antiretroviral therapy in the middle aged and elderly | Q37419826 |
| | Pharmacokinetics and drug metabolism in the elderly | Q37514319 |
| | Interventions to improve medication reconciliation in primary care. | Q37593799 |
| | Helping patients simplify and safely use complex prescription regimens | Q37670149 |
| | Upper gastrointestinal endoscopic findings in the era of highly active antiretroviral therapy | Q37690396 |
| | Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations | Q37695244 |
| | Use of digoxin for heart failure and atrial fibrillation in elderly patients | Q37845004 |
| | Lipid metabolism in treated HIV Infection | Q37887881 |
| | Polypharmacy in elderly patients with cancer: clinical implications and management. | Q37899374 |
| | Summary report from the Human Immunodeficiency Virus and Aging Consensus Project: treatment strategies for clinicians managing older individuals with the human immunodeficiency virus | Q38008447 |
| | Medication use and associated risk of falling in a geriatric outpatient population | Q38032832 |
| | A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience | Q38038817 |
| | Update on rifampin, rifabutin, and rifapentine drug interactions | Q38058540 |
| | High prevalence of radiological vertebral fractures in HIV-infected males. | Q39530457 |
| | Adherence to protease inhibitor therapy and outcomes in patients with HIV infection | Q39605935 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | human ageing | Q332154 |
| | polypharmacy | Q1895998 |
| | human immunodeficiency virus infectious disease | Q18556697 |
| P304 | page(s) | 749-763 | |
| P577 | publication date | 2013-06-21 | |
| P1433 | published in | Clinical Interventions in Aging | Q5133768 |
| P1476 | title | Polypharmacy in the HIV-infected older adult population | |
| P478 | volume | 8 | |